1756-8722-2-S1-A3 1756-8722 Meeting abstract <p>New insights on low-grade and T-cell lymphoma</p> Tse William william.tse@uchsc.edu

University of Colorado Cancer Center, Denver, CO, USA

 Journal of Hematology & Oncology <p>Current trends in leukemia, lymphoma, myeloma and ITP: updates and highlights from ASH 2008</p> Delong Liu Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1756-8722-2-S1-info.pdf <p>Current trends in leukemia, lymphoma and myeloma</p> White Plains, NY, USA 31 January 2009 1756-8722 2009 2 Suppl 1 A3 http://www.jhoonline.org/content/2/S1/A3 10.1186/1756-8722-2-S1-A3 26 6 2009 2009 Tse; licensee BioMed Central Ltd.

The advances in low-grade lymphoma & T-cell lymphoma from the 2008 ASH meeting were presented. These included therapeutic regimens for low grade lymphoma, frontline bendamustine plus rituximab data, radioimmunotherapy consolidation in advanced disease, idiotype vaccine, and other novel therapeutic agents such as next generation anti-CD20 GA101, syk inhibitor Fostamatinib in treatment of low-grade lymphoma. In T-cell lymphoma, updates were discussed on phase II HOVON 69 trial data of combination of alemtuzumab/CHOP, pralatrexate and romidepsin for relapsed/refractory PTCL, L-asparaginase-containing regimen for extranodal NK/T-cell lymphoma.